Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected ...

Moderna stock has reached day 5 of a consecutive winning streak, with total gains during this time reaching a 13% return.

The story of the pharmaceutical company Moderna almost reads like a Hollywood screenplay. In its relatively short life, it ...

A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled ...

Q3 earnings beat estimates but pipeline setback and lower 2025 guidance raise concerns. Full analysis of results and outlook.

In this week's STATus Report, STAT reporters Jason Mast and Damian Garde discuss the challenges facing Moderna — and what could be in store for its third act.

Moderna integrates extensive research and development with both in-house and partner manufacturing to rapidly develop and ...

In the past week, Moderna reported third-quarter 2025 earnings with revenue at US$1.02 billion, down sharply from the ...

Telemark Asset Management, LLC established a new position in Moderna ( MRNA +1.10%), acquiring 500,000 shares valued at approximately $12.91 million as of September 30, 2025, according to a November ...

The first was a one-time stock option exchange program for non-Executive Committee employees, which received significant support from stockholders. The second proposal allowed for the adjournment of ...

The 9 therapeutics stocks we track reported a mixed Q3. As a group, revenues beat analysts’ consensus estimates by 5.7%. In ...

Strong financial position with cash, cash equivalents and marketable securities of $93.7M Moderna litigation U.S. trial scheduled for March ...